ANGIOMAX(bivalirudin) Injection
ANGIOMAX Rx
Miscellaneous hematological agents 
Only 4 drugs may be compared at once
Generic Name and Formulations:
Bivalirudin 250mg/vial; pwd for IV inj after reconstitution and dilution.
Company:
The Medicines Company
Select therapeutic use:
Indications for ANGIOMAX:
Anticoagulation with concomitant aspirin in: unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA); patients with, or at risk of, heparin–induced thrombocytopenia (HIT) and thrombosis syndrome (HITTS) undergoing percutaneous coronary intervention (PCI), and in patients undergoing PCI with provisional use of glycoprotein IIb/IIIa (GPI).

Adult:
Give with aspirin 300–325mg daily: initiate 0.75mg/kg IV bolus (may give additional bolus of 0.3mg/kg after 5mins, if needed in those without HIT/HITTS), followed by 1.75mg/kg/hr for duration of procedure. May continue infusion up to 4hrs post-procedure; after 4hrs, may give additional infusion of 0.2mg/kg/hr up to 20hrs, if needed. Renal impairment: CrCl <30mL/min: reduce infusion rate to 1mg/kg/hr; hemodialysis: 0.25mg/kg/hr.

Children:
Not established.

Contraindications:
Active major bleeding.

Warnings/Precautions:
Consider stopping if symptoms of bleeding occur. Increased risk of thrombus formation with brachytherapy. Diseases associated with an increased bleeding risk. Monitor for acute stent thrombosis and signs/symptoms of MI in STEMI patients following PCI. Renal impairment. Pregnancy (Cat.B). Nursing mothers.

Interactions:
Increased bleeding risk with warfarin, heparin, thrombolytics. Interferes with INR measurements.

Pharmacological Class:
Anticoagulant.

Adverse Reactions:
Bleeding, back pain, pain, headache, GI upset, hypo- or hypertension, inj site pain, urinary retention.

Generic Availability:
YES

How Supplied:
Single-use vial—1